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Abstract
Background:  In chronic disease, health information technology promises but has yet to
demonstrate improved outcomes and decreased costs. The main aim of the study was to determine
the effects on mortality and cost of an electronic patient record used in daily patient care in a model
chronic disease, End Stage Renal Disease, treated by chronic maintenance hemodialysis. Dialysis
treatment is highly regulated, and near uniform in treatment modalities and drugs used.
Methods: The particular electronic patient record, patient-centered and extensively coded, was
used first in patient care in 3 dialysis units in New York, NY in 1998, 1999, and 2000. All data were
stored "live"; none were archived. By December 31, 2006, the patients had been treated by
maintenance hemodialysis for a total of 3924 years. A retrospective analysis was made using query
tools embedded in the software. The United States Renal Data System dialysis population served
as controls. In all there were 1790 patients, with many underlying primary diseases and multiple
comorbid conditions affecting many organ systems. Year by year mortality, hospital admissions, and
staffing were analyzed, and the data were compared with national data compiled by the United
States Renal Data System.
Results: Analyzed by calendar year after electronic patient record implementation, mortality
decreased strikingly. In years 3–9 mortality was lower than in years 1–2 by 23%, 48%, and 34% in
the 3 units, and was 37%, 37%, and 35% less than that reported by the United States Renal Data
System. Clinical staffing was 25% fewer per 100 patients than the national average, thereby lowering
costs.
Conclusion: To our knowledge, this is the first demonstration that an electronic patient record,
albeit of particular design, can have a favorable effect on outcomes and cost in chronic disease. That
the population studied has many underlying diseases affecting all organ systems suggests that the
electronic patient record design may enable application to many fields of medical practice.
Background
Care of chronic disease patients now predominates in
medical practice, and accounts for >75% of US $2.1 tril-
lion medical care costs [1]. Health information technol-
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ogy is believed essential in improving outcomes and
decreasing costs [2,3]. Although an integrated electronic
medical record, performance measures, and active per-
formance monitoring has been associated with improved
quality measures [4-6], hopes for effects on healthcare
quality, efficiency, and costs have yet to be realized. One
recent systematic review concluded that the evidence was
sparse [7], another found little evidence that computer-
ized clinical decision support has effected patient out-
comes [8]. We found no literature on effects of electronic
medical records on mortality in any chronic disease.
Over 30 years ago Fries concluded that in chronic disease:
"a major failure of the traditional chart is its inability to
indicate adequately complex temporal relationships
between clinical, laboratory, and therapeutic events [9]."
To address these complex temporal relationships, paper
spreadsheets were used to manage clinical, laboratory,
histological, and therapeutic details sequentially in renal
involvement in systemic lupus erythematosus [10]. This
approach was expanded to develop a new comprehensive
patient-centered paper record to facilitate understanding
of systemic and renal manifestations of diseases. After
extensive testing it was converted to electronic form [11].
Discrete medical practice details for diseases affecting
multiple organ systems were transformed into coded data,
enabling rearrangement of data elements to facilitate clin-
ical practice and observations over many years.
End Stage Renal Disease (ESRD) is complex, costly, and
affects more than 500,000 patients in the United States
[12]. As a model to test effects of this comprehensive,
coded and analyzable, electronic patient-centered record
(EPR) in chronic disease, ESRD has unique advantages.
First, it is highly regulated, with frequent routine and ad
hoc State and Federal oversight; treatment adequacy mark-
ers must be reported. Second, to start dialysis treatment,
patients must meet mandated criteria. Third, treatments,
devices, and drugs used are largely standardized. Fourth,
dialysis procedures are also largely standardized and, for
the most part, operator independent. ESRD often results
from primary disease conditions such as diabetes melli-
tus, HIV/AIDS, multiple myeloma, systemic lupus ery-
thematosus, arteriosclerosis, and hypertension; comorbid
conditions affecting many organ systems are universal.
Each patient requires lifetime care, receives 140–156 treat-
ments and accumulates up to 11,600–21,000 individual
data items yearly [13], is cared for in many locations by
caregivers from several disciplines. Mandatory reporting
ensures that the United States Renal Data System provides
a national database and mortality standard with which to
compare results. Moreover, 68–70% of US patients are
treated in dialysis units owned by 5 (since recent mergers,
3) large dialysis "chains" [12]; each deploys an electronic
medical record [14-17].
We here test the hypothesis that "Successful management
and treatment of the patient and the important individual
manifestations of a chronic disease require complex feed-
back systems that relate therapeutic interventions to clini-
cal and laboratory information relevant to multi-organ
systems over prolonged periods" [11]. We analyzed retro-
spectively data collected during patient care from 1998
onward using the EPR, enhanced continually since 1976
[13,18-21]. This study EPR was the test instrument.
USRDS mortality data provided contemporaneous con-
trols [12]. Favorable effects on mortality and cost were
observed on ESRD patients treated by chronic mainte-
nance hemodialysis (HD) for a total of 3,924 years over a
9-year period.
Methods
The setting
The study was done in 3 dialysis units managed by The
Rogosin Institute (New York, NY), affiliated with New
York Presbyterian Hospital and Weill Medical College of
Cornell University. All provide treatment by in-center
chronic HD. Unit A also trains and treats patients by peri-
toneal dialysis, home HD, and nocturnal self-HD. Eight
full-time salaried Rogosin Institute staff nephrologists,
who also care for renal and transplant patients, teach, and
do clinical research, and 2 nurse practitioners care for
patients in Unit A. In Unit B, there are 1 to 2 Rogosin
nephrologists, 2 to 5 in private practice, and 1 nurse prac-
titioner. In Unit C, the 3 nephrologists are in private prac-
tice.
Participants
The patients were all 1790 patients treated by chronic
maintenance HD from 91 days after ESRD start.
Design of the study
The electronic patient record (Disease Manager Plus™,
MIQS® Inc, Boulder, CO) employs a relational database
(Sybase® Adaptive Server Enterprise, Sybase, Inc., Dublin,
CA), running on a server computer (Sun® Microsystems,
Santa Clara, CA). It is accessed using a custom toolset (4D,
Inc., San Jose, CA) from client personal computers in dial-
ysis units, renal and transplantation practice, physician
offices, hospital, and home. All clinical, administrative,
and financial information is immediately accessible at all
times on patients ever entered into the database. It serves
all kidney disease care, including dialysis and transplanta-
tion. Subject to security considerations, lifetime patient
data relevant to pertinent caregiver needs are accessed
whenever and wherever needed. The security ensures con-
fidentiality for clinical and financial information and for
integrated electronic mail. Laboratory test results, radiol-
ogy reports, pathology reports, and dialysis machine data
download automatically into the database via MIQS-
designed electronic interfaces. Dialysis machine data ena-BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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ble on-line chair-side and remote real-time monitoring
including home nocturnal HD [21].
Coded data elements include diagnoses, procedures,
symptoms, signs, medications, allergies, and hospitaliza-
tions. Patient-specific ICD-9-CM codes record reason(s)
medications are prescribed and patients admitted to hos-
pital. Notes are charted in free text or using templates.
Advance directives, living will, do not resuscitate, treat-
ment consent, and other documents are stored in the
database and readily accessible. HD treatment screens
record all details. HD orders and medications to be given
during HD automatically populate treatment screen
fields.
To provide clinically useful point-of-care reports embed-
ded query tools are incorporated to organize data quickly
in any way desired over any time period, to make knowl-
edge available about individual patients, and groups.
Reports that can be updated and organized at the point-
of-care are user-designed to facilitate clinical decisions
based on timely, complete, relevant, patient-specific,
time-oriented data.
The electronic starting point for patient encounters dis-
plays all relevant historical information including reports,
medications, allergies, and patient-specific and rules
based alerts and reminders. Encounters, tailored to spe-
cific functions such as HD, peritoneal dialysis, chronic
kidney disease, and transplantation facilitate data entry
and communication with others, e.g., referring physi-
cians. Individual patient reports accessible on encounter
and HD treatment screens include contemporaneous
medications, comprehensive lifetime lists of diagnoses,
surgical procedures, diagnostic procedures, allergies,
adverse drug reactions, immunizations, and hospitaliza-
tions (Figures 1 and 2). Others display data over time in
spreadsheet format from domains including signs, symp-
toms, medications, laboratory tests, HD orders and treat-
ments, diagnoses, procedures, and hospitalizations
(Figure 3).
Patient treatment groups, a special software functionality,
define patients receiving treatment courses by in-center
HD, other dialysis modalities, kidney and pancreas trans-
plants. An in-center HD group is defined by dates of first
and last HD in a treatment course. Reason the course
ended is charted from a coded list that includes patient
expired, recovered renal function, transferred to another
dialysis unit, transferred to another group, e.g., kidney
transplant.
Data Analysis
Reports that incorporate information from multiple infor-
mation domains were used for data analysis on patient
groups. An integrated patient selection query tool enabled
selection of cohorts for inclusion in reports. Among selec-
tion criteria were demographic elements, locations, alive
or expired within a defined time range, presence or
absence of ≤3 patient groups and ≤3 ICD coded diseases
and procedures.
The Treatment History with Adjusted Dates report ena-
bled much analysis. It adjusted dates automatically to first
and last days of the chosen period, calculated days in the
group, and displayed why the group ended. For the
present analysis it was modified by adding age (at treat-
ment history start), ethnicity, gender, ESRD date (first ever
treatment by dialysis or transplantation), date of death,
primary cause of ESRD. ESRD vintage was calculated as
(Start date of dialysis in the period of study – ESRD date).
The report was generated using the patient selection query
tool to select the pertinent HD cohort, Unit A, B, or C,
individual calendar year or full 6–9 year spans. Days in
the group were summed and average age calculated. Saved
as an ASCII file, it was imported for further analysis into
Microsoft® Excel® or SAS® JMP™.
USRDS reports data only from the 91st day after start of the
first dialysis treatment [12]. To enable comparable analy-
ses, data were sorted first by (Start date – ESRD date), and
second by treatment group days. Patients starting dialysis
within <91 days and with <91 dialysis treatment days
were excluded. Those starting dialysis within 91 days of
ESRD date were included if treated for >90 days; treatment
group days were reduced by days prior to the 91st, as in
USRDS.
The reason treatment was discontinued was examined,
using the following conventions:
￿ Kidney transplants: Patients were deemed alive at the
end of the prior dialysis course.
￿ Deaths: Date treatment was discontinued because
patient expired was checked with date of death recorded
under patient demographics. Known death within 30 days
of transfer to hospital, nursing home, hospice or another
dialysis unit was ascribed to the previous modality.
￿ Transfers to other units for continuing dialysis care: The
database was searched for site of future dialysis care, and
latest recorded patient-caregiver contact. Time from trans-
fer to last documented contact was calculated. Patients
documented alive ≥ 6 months after transfer were treated
for analysis as alive at relevant study year-end. Patients
with no such information available were considered "lost
to follow up"BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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"Bird's eye view" of the first part of the lifetime history of a patient treated by in-center HD since August 1999 Figure 1
"Bird's eye view" of the first part of the lifetime history of a patient treated by in-center HD since August 1999. Disease condi-
tions related to the kidney and urinary tract, and disease conditions and procedures related to dialysis are displayed. Organized 
for a dialysis patient, they are displayed chronologically under the corresponding headings. ICD-9-CM codes and descriptors, in 
upper case, are used to display the diagnoses and procedures. Brief comments, which had been added to the entry screens, 
appear in lower case beneath the ICD coded descriptors where they provide clinical color for the codes,BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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"Bird's eye view" of the second part of the lifetime history of a patient treated by in-center HD since August 1999 Figure 2
"Bird's eye view" of the second part of the lifetime history of a patient treated by in-center HD since August 1999. Disease 
conditions other than those related to kidney and urinary tract, allergic reactions, surgical procedures, diagnostic procedures, 
vaccinations, and hospitalizations are displayed. Reports of this type in which data are organized relevant to the needs of other 
fields such as cardiovascular disease, hematology, social work, etc are also immediately available.BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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Report designed to enable caregivers to review the effects of treatment Figure 3
Report designed to enable caregivers to review the effects of treatment. It displays relevant "core" data of one patient for the 
present and the previous five months. Under headers weight, blood pressure, and dialysis treatment (with sub headers treat-
ment time, blood processed, and Kt/V) the data derive from HD orders, HD treatments, and laboratory test results. They are 
arranged to provide feedback between orders for and treatments delivered. Relevant lab test results and medications are also 
displayed to enable review of common problems under headers calcium/phosphorus, anemia/hematology, and electrolytes/
nutrition. Reports with an expanded relevant data set are immediately available for more detailed review of each of these 
problems.BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
Page 7 of 15
(page number not for citation purposes)
Calculation of Mortality
Mortality per 1000 patient years was calculated for each
individual study unit in each calendar year, as is done by
USRDS, by dividing the number of deaths in each individ-
ual year by the total time in years that the patients were
treated by HD in that calendar year, and multiplying by
1000.
Data Verification
Analyses were made on several occasions. Dubious or
missing values were checked and corrected as necessary in
the EPR. Many coded values were missing because data
had been charted as text only; coded values were entered
from physician text notes. For final analysis, reports were
run by individual calendar years and the entire 7–9 year
period.
Study Approval
The study was approved by the Institutional Review Board
of Weill Medical College of Cornell University.
Results
Patients
The subjects of this report are 1790 patients treated by
chronic maintenance hemodialysis from 91 days after
ESRD start. Their mean age of 59.2 ± 16.16 (SD) years was
2.1 years older than that of USRDS (Table 1). There were
more females, fewer Whites, more Blacks, more other/
unknown racial groups, and more Hispanics. The propor-
tion with ESRD due to diabetes mellitus type I was lower,
whereas that due to diabetes mellitus type II, hyperten-
sion, glomerulonephritis, and polycystic kidney disease
reflected national data (Table 2).
Patients in the 3 Units differed in several characteristics.
They were younger in Unit A than in B and C (Table 3). In
Unit C more started treatment within 91 days of ESRD
than in A and B, fewer within >2 years. In Unit A there
were more with diabetes mellitus type I, glomerulone-
phritis, polycystic kidney disease, and fewer with diabetes
mellitus type II (Table 4). There were fewer with hyperten-
sion in Unit C.
Mortality
Over the entire study period, 13 patients recovered suffi-
cient function to discontinue dialysis (Table 5). In Unit A,
12.7% of patients received a kidney transplant, 7.7% and
9.1% respectively in Units B and C. More Unit C patients
(19%) were lost to follow up than A (11%) and B (8%)
patients. In Units A, B, and C mortality was respectively
156, 171, and 173 per 1000 patient years, lower than the
1998–2005 USRDS HD mortality (229–241 per 1000
patient years) [12].
As might be expected when the number of patients in each
unit was relatively small, mortality did vary substantially
year-to-year (Table 6). Nevertheless, save for year 2001 in
Unit A, mortality decreased strikingly in each Unit, from
Table 3: Selected patient demographic data, at first HD 
treatment, in each dialysis unit
Unit A
(1998–2006)
Unit B
(1999–2006)
Unit C
(2000–2006)
Number of patients 858 515 417
Age at start of first 
HD treatment during 
the study period 
(years)
56.9 60.4 62.5
Gender 
(male: female) (%)
53.7:46.3 52.6:47.4 51.8:48.2
Race (White: Black: 
Other/Unknown) (%)
40.9:38.2:20.9 49.1:23.1:27.
8
37.4:49.2:13.6
Hispanic (%) 19.1 17.8 13.4
Dialysis vintage 
≤ 91 days (%)
41.2 41.9 65.0
Dialysis vintage
> 2 years (%)
40.6 33.2 17.0
Dialysis vintage 
> 5 years (%)
23.9 16.3 4.7
Table 1: Selected patient demographic data, at first HD 
treatment, between January 1 1998 and December 31, 2006
All Units USRDS*
Number of patients 1790 709,259
Mean age at start of first HD 
treatment during the study period 
(years)
59.2 57.1
Gender (male:female) (%) 52.9:47.1 54.7:45.3
Race (White: Black: Other/Unknown) 
(%)
42.4:36.4:21.2 63.3:28.5:8.2
Hispanic (%) 17.4 12.5
*USRDS data are prevalence of all ESRD patients for the years 
1998–2005 combined.
Table 2: Primary disease causing ESRD
All Units (%) USRDS* (%)
Diabetes mellitus Type 1 (juvenile) 4.0 6.3
Diabetes mellitus Type 1I (adult onset 
or unspecified)
32.4 29.5
Glomerulonephritis 14.6 15.7
Hypertension 24.2 22.3
Systemic lupus erythematosus 1.9 1.9
Polycystic kidney disease 4.2 4.2
AIDS nephropathy 1.9 0.6
Neoplasm (renal and urological), 
myeloma, amyloidosis
1.6 0.9
Hydronephrosis, obstruction, infection 2.9 4.6
*USRDS data are prevalence of all ESRD patients for the years 
1998–2005 combined.BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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2000 onward in Unit A, 2001 onward in B, and 2002
onward in C. Considered by year of EPR deployment,
mortality was, with a single exception (Unit A, year 4),
lower from year 3 onward.
The effect of year-to-year variation may be expected to be
less when the results are recapitulated in periods of two or
more successive years. Mortality for years 1–2, 3–4, and
5–9 of EPR deployment is summarized in Figure 4. In
Unit A, mortality in years 3–4 was 198 per 1000 years,
similar to that in years 1–2. In years 5–9, mortality was
129 per 1000 years, a reduction of 35%. In Unit B, mor-
tality was 44% lower in years 3–4 than in years 1–2, and
49% lower in years 5–8. In Unit C mortality was 36%
lower in years 3–4 than in years 1–2, and 32% lower in
years 5–7. By contrast, the contemporaneous USRDS mor-
tality remained constant around 237 per 1000 years from
1998 to 2003, and decreased slightly to 232 and 229 per
1000 years in 2004 and 2005.
As a test of trend, the mortality data from all 3 Units were
then combined and a simple regression analysis of mor-
tality per 1000 years was calculated (Figure 5). This pro-
duced a regression of 244.4 – 14.18 per year of study EPR
use (adjusted r2 = 0.72, p = 0.0022). Thus, the mortality
decreased by 28 per thousand every two years. It cannot be
assumed, however, that this trend will continue with
more extended use of the study EPR.
USRDS mortality calculations include deaths in hospitals,
nursing homes, other dialysis units, and elsewhere. Com-
plete knowledge of patients transferred is not available to
individual dialysis units, nor was it for this analysis. Of
351 patients transferred to other units, 113 were docu-
mented alive an average of 2.32 years later. As some of the
other 238 patients may have died and because death
might have been attributed to Unit A, B, or C, mortality
was recalculated, assuming that 25%, (approximating the
USRDS 23.7%) died by end of the calendar year. So calcu-
lated, the difference in mortality between years 3–9 inclu-
sive of electronic patient record deployment and years
1–2 changed little; it was lower by 17% in Unit A, 43% in
Unit B, and 26% in Unit C.
Mortality in years 3–9 inclusive was recalculated for the 3
Units combined assuming that 25%, 50%, 75%, or 100%
of those lost to follow up died by end of the calendar year
in which they were transferred (Figure 6). Mortality would
have been 31%, 26%, 20%, and 14% less than USRDS
assuming respectively that 25%, 50%, 75%, or 100% of
those lost to follow up died.
Hospital Admissions
Over the entire study period, patients in Units A and B
were admitted to hospital an average of 1.24 (range 1.08
to 1.39) and 1.32 (range 1.01 to 1.65) times per year, i.e.,
39% and 35% less frequently than the USRDS rate of 2.04
[12]. Patients in Unit C were admitted to hospital 2.97
times per year in years 1–2 of EPR deployment, a rate
reduced to 2.01 in years 3–7.
Staff
Since 2004 patient and staff counts as of December 31 of
each year have been provided in the annual Dialysis Facil-
ity report by the ESRD Network of New York. Patients
treated by both HD and peritoneal dialysis are included.
In 2004 and 2005 clinical staff numbered 14.1, 13.4, and
Table 5: Summary of patient outcomes in each dialysis unit over the 7–9 year period
Unit A
(1998–2006)
Unit B
(1999–2006)
Unit C
(2000–2006)
Years of observation 1926.7 1046.2 951.0
Recovered renal function 4 3 6
Received a kidney transplant 109 40 38
Followed in the database after transfer to peritoneal dialysis, home hemeral 
or nocturnal hemodialysis
41 3 3
Known to be alive after transfer to another dialysis facility 79 22 12
Lost to follow up after transfer to another dialysis facility 102 50 86
Deaths 303 178 164
Deaths per 1000 patient years 157.3 170.1 172.5
Table 4: Primary disease causing ESRD in each dialysis unit
Unit A (%) Unit B (%) Unit C (%)
Diabetes mellitus Type 1 5.7 2.3 2.4
Diabetes mellitus Type 1I 21.5 40.5 45.0
Glomerulonephritis 20.6 10.5 7.2
Hypertension 26.1 26.2 18.0
Systemic lupus erythematosus 2.2 1.4 2.1
Polycystic kidney disease 5.7 3.3 2.2
AIDS nephropathy 1.6 2.1 2.2
Neoplasms, myeloma, 
amyloidosis
1.9 1.0 1.9
Hydronephrosis, obstruction, 
infection
3.5 1.8 2.9BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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13.5 per 100 patients in Units A, B, and C respectively. In
those two years the national average was 18.41 clinical
staff per 100 dialysis patients [12]. The data for the three
study Units were combined to compare with the USRDS
data (Table 7). Clinical staff in the study Units numbered
13.79 per 100 patients, i.e., 25.1% fewer than the national
average. Nurses, patient care technicians, dietitians, and
social workers were respectively 29.1%, 24.7%, 18.6%
and 8.5% fewer per 100 patients than the USRDS.
Discussion
Using an earlier EPR version in a single dialysis unit, we
reported mortality 25% below the 1980–1989 national
average [13,22]. Both EPR software and the national data-
base have been greatly enhanced since. The present study
is the first demonstration, to our knowledge, that use of
an electronic patient record in any chronic disease practice
favorably effects mortality.
Stead wrote recently that improvements from information
technology implementation "are difficult to quantify in a
practice while changing people's roles, process, and tech-
nology at the same time. Most measures have an immedi-
ate impact on process whereas many of the expected
benefits are in long-term clinical outcomes [8]." We had
no a priori knowledge of time needed from initial EPR
implementation to development of a measurable out-
come, particularly when dependent on many underlying
diseases, comorbid factors, care, and other variables. A
favorable effect by year 3 seems reasonable because staff
had to learn to use and become comfortable with the tech-
nology while continuing daily patient care activities, and
lower mortality in year 3 is likely to reflect improved qual-
Table 6: Patients treated, treatment duration, and mortality by calendar year in each dialysis unit. USRDS data are shown for 
comparison
Y e a r s 1 9 9 81 9 9 92 0 0 02 0 0 12 0 0 22 0 0 32 0 0 42 0 0 52 0 0 6
Number of patients treated during each year
U n i t  A 2 7 92 3 62 9 42 9 52 6 82 8 73 1 33 1 73 4 0
Unit B NA 112 152 157 166 160 167 232 258
U n i t  C N AN A1 5 41 7 11 7 11 8 01 9 01 9 21 9 3
Mean age (years) at start of HD treatment in each year
Unit A 56.9 58.7 57.3 57.2 56.1 56.0 57.3 56.7 58.2
Unit B NA 60.7 59.9 59.5 60.0 59.7 60.8 61.5 62.9
Unit C NA NA 62.5 63.4 64.2 61. 9 61.5 62. 6 62.5
USRDS* 56.2 56.5 56.8 57.0 57.3 57.5 57.7 57.9 NA
Duration of treatment (years)
Unit A 193.5 173.8 221.1 208.1 207.9 219.4 232.8 235.3 244.8
Unit B NA 81.0 100.2 118.6 121.6 121.9 130.6 169.3 202.9
Unit C NA NA 101.7 126.5 139.9 144.8 145.9 148.8 145.2
Number of deaths
U n i t  A 3 63 53 84 72 91 93 83 42 7
U n i t  B N A 2 52 61 72 12 11 42 72 7
U n i t  CN A N A 2 72 62 02 22 42 32 2
Mortality per 1000 patient years
Unit A 186.1 201.4 171.8 225.8 139.4 86.2 163.2 144.5 110.8
Unit B NA 308.7 259.5 143.4 172.7 172.3 107.2 159.5 133.1
Unit C NA NA 265.5 205.6 142.9 151.9 164.5 154.5 151.5
USRDS** 234 241 236 238 237 236 232 229 NA
* USRDS age data are mean age of all prevalent ESRD patients (both dialysis and transplant) in each calendar year.
** USRDS mortality data are for patients treated by HD.BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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ity of care in year 1 and/or 2. This was clearly evident in
Units B and C by year 3, and in Unit A by year 5. Lower
mortality was observed consistently thereafter for 5 years
in Unit A, 6 years in Unit B, and 5 years in Unit C.
That mortality of the study population was less than
USRDS might be explained by differences between demo-
graphic and comorbid factors of the study and USRDS
populations. To test for this possibility we obtained stand-
ardized mortality ratios (SMR) generated by the Univer-
sity of Michigan Kidney Epidemiology and Cost Center
[23]. Since 2001, SMR has been calculated from a Cox
model, adjusting for age, race, ethnicity, gender, diabetes,
ESRD duration, patient comorbidities and body mass
index at incidence, and population death rates. SMR
trends in 2001–2006 were similar to those in our analysis.
Compared on a year-by-year basis, SMR and the study
patient mortality correlated significantly (adjusted r2 =
0.30, p = 0.011), suggesting that the decreased mortality
in 2001–2006 was not due to differences in demographic
and comorbid factors of the study and USRDS popula-
tions. The demographic and comorbid factors of the pop-
ulation of each Unit, which varied year-to-year almost
imperceptibly, cannot explain the lower mortality
observed in each Unit. This supports the view that the
lower mortality when compared with USRDS was not due
simply to a center effect.
We sought to identify other factors such as change in man-
agement patterns or dialysis technology that might have
contributed to improved outcomes; no obvious ones were
found. Increased number and/or professional qualifica-
tion of patient care staff is one possible explanation; this
was not the case. As in an earlier report [13], there was a
favorable effect on staff efficiency (Table 7). Compared
with years 1–2 hemoglobin and serum albumin, indica-
tors of patient well being, changed little: hemoglobin
increased 5% in years 3–9; serum albumin and serum iron
were unchanged. Kt/V, a widely used index of dialysis ade-
quacy, increased in years 3–9 by 11%, 2%, and 4% in
Units A, B, and C respectively. Mortality decreased most in
Units B and C, where the change in the index was very
small.
Conclusion
How is it possible that the particular study EPR can have
played so important a role? Two properties of the EPR are
crucial to understanding: it is patient-centered, and it is
extensively coded.
Mortality in years 3–9 combined, with varying assumptions  about mortality within a calendar year among patients "lost  to follow up" Figure 6
Mortality in years 3–9 combined, with varying assumptions 
about mortality within a calendar year among patients "lost 
to follow up".
Mortality rate, by years of electronic patient record deploy- ment, in dialysis Units A, B, and C Figure 4
Mortality rate, by years of electronic patient record deploy-
ment, in dialysis Units A, B, and C. The mortality rate is com-
pared with that reported by USRDS (horizontal line).
Data from all 3 dialysis units combined were used to analyze  regression of mortality per 1000 patient years on years of  study electronic patient record (EPR) use Figure 5
Data from all 3 dialysis units combined were used to analyze 
regression of mortality per 1000 patient years on years of 
study electronic patient record (EPR) use.BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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The patient-centered study EPR captures, stores, and
retrieves on-line and without delay all patient-specific
medical data from multiple information domains includ-
ing diagnoses, procedures, symptoms, signs, medications,
orders, test results, and dialysis treatments [11,18]. It does
so for all venues of care and for care provided by any car-
egiver, especially important in dialysis where all patients
have multiple systemic diseases that need repeated evalu-
ation and treatment by multiple providers over many
years at a variety of sites. Unlike disease registries that usu-
ally focus on a single disease entity and its assumed com-
plications, the study EPR is a generalized model of
medicine that makes no assumption about future co-mor-
bidities, complications, or outcomes in its data model. On
the contrary it captures, stores, and retrieves any or all that
might occur.
Extensive coding of the study EPR is essential to its utility.
The ultimate products of virtually all electronic medical
records are notes similar to those in a paper chart; data
cannot be added or rearranged to explore varied and unex-
pected facets of the patient's condition(s), nor can they be
viewed over time. The products of the study EPR are
reports that contain many domains of data appropriate to
a particular disease at any particular moment in time in
care of the patient (Figures 1, 2, and 3). Their function is
not static documentation of a moment; rather it is to dis-
play what has occurred over time, to evaluate and/or
change the intervention, and then repeat the process.
Essentially the report facilitates continuous quality
improvement at the point-of-care [24].
These properties of the study EPR made possible:
(1) Computerized data entry with, and generation of, clin-
ically relevant reports thereby eliminating communica-
tion and process errors.
(2) All information needed for skilled clinicians to make
best judgments about patient care was always available
immediately in clinical reports. Data in reports were com-
plete, from multiple domains, and were viewed sequen-
tially over time (Figure 3). We believe that complete,
accurate, up-to-date, and focused time-oriented informa-
tion had a favorable effect on work flow, facilitated under-
standing of the complex interrelations that effect
outcome, enabled clinicians to make best management
decisions, and therefore favorably impacted survival.
(3) Aberrant findings in one or a few patients were easily
recognized (Figure 7), and their prevalence investigated
rapidly [25,26]. This knowledge led to development of
reports (Figure 8) and rules based alerts and reminders
(Figure 9) for use in daily clinical practice. Knowledge so
derived also enabled survival analysis [27], generated new
understanding of a disease [25], decreased symptoms,
improved well being [13,18,22], and detected and solved
unexpected problems [19].
(4) Development of protocols and their timely updating
as new data became available. Recognition of a high prev-
alence of iron deficiency in anemic epoietin treated dialy-
sis patients led to systematic study, with repeated
feedback, of intravenous iron repletion. Unexpected find-
ings included: a very significant rise in serum albumin –
an excellent outcome marker [28] – and in indirectly
measured muscle mass; iron deficiency without iron defi-
ciency anemia; decreased hospital admissions and stay
Table 7: Counts of patients and patient care staff on December 31, 2004 and December 31, 2005
Patient care staff Staff per 100 Patients
Study Units* USRDS Study Units USRDS
Patients**
624 326, 574 NA NA
Staff (Full-time equivalents)***
Total patient care staff 86 60,112 13.79 18.41
Nurses (RNs and LPNs) 34 25,109 5.45 7.69
Patient care technicians 39.5 27,466 6.33 8.41
Dietitians 5.75 3,675 0.92 1.13
Social workers 6.75 3,863 1.08 1.18
* Data are means of counts at the end of years 2004 and 2005.
** Patients treated by hemodialysis and by peritoneal dialysis.
*** Staff who care for hemodialysis and peritoneal dialysis patients. One part-time employee is considered equivalent to 0.5 full-time employee.BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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[26]. This knowledge was disseminated in the study units
when one of us (JAL) joined the Rogosin staff.
A trial of the study EPR with a randomly selected control
group has the potential to provide evidence of cause and
effect but would be difficult to design and control, and
expensive to carry out for the many years needed. The
present study compares data between groups and across
time periods and uses two national standards, USRDS
data [12] and standardized mortality ratio data [23], for
contemporaneous controls. Unadjusted and adjusted
mortality decreased comparably in 3 practice environ-
ments using the study EPR. Nationwide, where 70% of
patients are treated by 3–5 corporations that use a tradi-
tional electronic medical record focused on management
and billing, there was no concurrent change. With the lim-
itations inherent in an observational study, the data pro-
vide evidence that benefits in long-term clinical outcomes
can be achieved with the study EPR although cause and
effect cannot be proven.
The study EPR had a favorable effect on mortality in ESRD
patients treated by dialysis. Are similar results possible in
other chronic diseases, and with other medical informa-
tion systems? The challenges are great, as reviewed
recently in a study of practice guidelines and quality of
care for older patients with multiple comorbid conditions
[29]. In 1977 we wrote, "At any time in the course of an
illness, the patient may develop one, or many of the uni-
verse of symptoms, physical signs, and laboratory abnor-
malities that occur in clinical medicine as a whole" [11].
The study EPR database, and its integrated query tools,
First treated by HD in January 1994, this 39 year old diabetic patient was transferred to a dialysis unit using the study EPR in  November 1995 Figure 7
First treated by HD in January 1994, this 39 year old diabetic patient was transferred to a dialysis unit using the study EPR in 
November 1995. He received intravenous (IV) iron in three 1 g courses between November 1995 and June 1996. A modest 
improvement in the hemoglobin level occurred, but transferrin saturation (TSAT, an important measure of iron deficiency), 
mean corpuscular volume (MCV), and serum albumin level (a predictor of mortality) remained low. Recognizing that conven-
tional IV iron replacement had been ineffective, 1 g courses of IV iron were again given starting in November 1996. With 
appropriate feedback, the courses were repeated whenever measures of iron deficiency were low. Not only was there an 
excellent hemoglobin response, but two unexpected findings were apparent: MCV increased to well above the normal range, 
and serum albumin increased to a range predictive of relatively low mortality. These observations were then confirmed in a 
large patient cohort [26].BMC Medical Informatics and Decision Making 2007, 7:38 http://www.biomedcentral.com/1472-6947/7/38
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were designed to enable deployment in many fields of
medicine and chronic diseases. If this and other EPR data-
bases are to yield comparable results, we believe it essen-
tial that they adhere closely to the dictum that the medical
record must be able to indicate complex temporal rela-
tionships between clinical, laboratory, and therapeutic
events [9], and in both individuals and groups of patients.
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